Achieve Life Sciences, Inc. (ACHV) – What Are Analysts Saying About This Stock?

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Free Report) have earned an average recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $15.50.

A number of equities research analysts have recently issued reports on ACHV shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a report on Wednesday, August 19th. Stifel Nicolaus set a $18.00 price objective on shares of Achieve Life Sciences and gave the company a “buy” rating in a research note on Tuesday, September 29th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $18.00 target price on shares of Achieve Life Sciences in a report on Wednesday, August 12th. UBS Group reiterated a “buy” rating on shares of Achieve Life Sciences in a research note on Wednesday, August 12th. Finally, Morgan Stanley initiated coverage on shares of Achieve Life Sciences in a report on Thursday, August 13th. They issued an “overweight” rating and a $13.00 price target for the company.

Get Our Latest Stock Analysis on ACHV

Achieve Life Sciences Price Performance

Achieve Life Sciences stock opened at $6.71 on Tuesday. The business’s 50 day simple moving average is $7.12 and its 200 day simple moving average is $5.73. Achieve Life Sciences has a 12 month low of $2.62 and a 12 month high of $8.64. The company has a market cap of $689.96 million, a price-to-earnings ratio of -4.33 and a beta of 2.42. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.87.

Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.09. Sell-side analysts forecast that Achieve Life Sciences will post -0.92 EPS for the current year.

Insider Buying and Selling at Achieve Life Sciences

In other Achieve Life Sciences news, Director Richard Stewart sold 20,626 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $8.49, for a total value of $175,114.74. Following the sale, the director owned 208,249 shares of the company’s stock, valued at $1,768,034.01. This trade represents a 9.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.80% of the company’s stock.

Institutional Investors Weigh In On Achieve Life Sciences

A number of large investors have recently added to or reduced their stakes in ACHV. Fifth Third Bancorp lifted its stake in shares of Achieve Life Sciences by 92.7% in the 3rd quarter. Fifth Third Bancorp now owns 4,413 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 2,123 shares during the last quarter. Legal & General Group Plc bought a new stake in Achieve Life Sciences during the 2nd quarter valued at $49,000. Steward Partners Investment Advisory LLC raised its holdings in Achieve Life Sciences by 394.7% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 12,032 shares of the biopharmaceutical company’s stock valued at $97,000 after buying an additional 9,600 shares during the last quarter. AXQ Capital LP boosted its position in Achieve Life Sciences by 65.6% during the 2nd quarter. AXQ Capital LP now owns 25,173 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 9,972 shares during the period. Finally, SLT Holdings LLC purchased a new stake in Achieve Life Sciences during the 3rd quarter valued at $89,000. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

(Get Free Report)

Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead candidate, cytisinicline, is an oral medication being studied to help people stop smoking and quit using nicotine-containing products, including e-cigarettes. Cytisinicline is a plant-derived compound that acts on nicotinic receptors in the brain. Achieve is evaluating it in clinical trials; it is not an approved commercial product. The company’s development efforts have focused primarily on the U.S. market.

Further Reading

Analyst Recommendations for Achieve Life Sciences (NASDAQ:ACHV)

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.